Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations
Paul K. Paik(Memorial Sloan Kettering Cancer Center), Xiuning Le(The University of Texas MD Anderson Cancer Center), Andreas Johne(Merck KGaA, Darmstadt (Germany)), Anthonie J. van der Wekken(University Medical Center Groningen), Egbert F. Smit(Dutch Cancer Society), Christopher Stroh(Universität Hamburg), Ji‐Youn Han(National Cancer Centre Japan), Alexis B. Cortot(Centre National de la Recherche Scientifique), Jyoti D. Patel(Memorial Sloan Kettering Cancer Center), PierFranco Conte(University of Padua), Santiago Viteri(Instituto Oncológico Dr. Rosell), Hiroshi Sakai(Hiroshima University), John V. Heymach(The University of Texas MD Anderson Cancer Center), Hélène Senellart(Institut Génétique Nantes Atlantique), Frank Griesinger(Carl von Ossietzky Universität Oldenburg), Dilafruz Juraeva(Merck KGaA, Darmstadt (Germany)), James Chih‐Hsin Yang(National Taiwan University Hospital), Julien Mazières(Université Toulouse III - Paul Sabatier), Rolf Bruns(Inserm), Leora Horn(Vanderbilt University), Byoung Chul Cho(Yonsei University), Rémi Veillon(Centre Hospitalier Universitaire de Bordeaux), Dariusz M. Kowalski(The Maria Sklodowska-Curie National Research Institute of Oncology), Niels Reinmuth(Asklepios Fachkliniken München-Gauting), Chen‐Liang Tsai(National Defense Medical Center), Jan P. van Meerbeeck(Antwerp University Hospital), Enriqueta Felip(Institut Català d'Ornitologia), Terufumi Kato(Taipei Veterans General Hospital), Marina Chiara Garassino(University of Chicago), Young‐Chul Kim(Chonnam National University Hwasun Hospital), J. Scheele(Center for Global Development), Josef Straub(Inserm), Yuh-Min Chen(National Yang Ming Chiao Tung University), Gee‐Chen Chang(National Yang Ming Chiao Tung University), Jo Raskin(Inserm)
Cited by 879
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k